Thursday, November 12, 2026

Memory Chip Shortages Hit Peak in Q1 2026, Delaying AI Infrastructure Rollouts

Memory supply constraints reached their peak in Q1 2026, preventing Intel and other AI hardware manufacturers from meeting surging demand driven by agentic AI workloads. Intel expects constraints to clear starting Q2 2026, while JPMorgan downgraded optical component makers on near-term pressure from the shortage.

LM Salvado

April 19, 2026

Memory Chip Shortages Hit Peak in Q1 2026, Delaying AI Infrastructure Rollouts
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Memory chip shortages peaked in Q1 2026, creating a bottleneck for AI infrastructure deployment as companies struggled to secure DRAM and high-bandwidth memory supplies needed for GPU systems and agentic AI workloads.1

Intel reported it cannot meet strong demand due to supply constraints expected to peak this quarter.1 The company projects constraints will clear starting in Q2 2026, leading to above-seasonal results in subsequent quarters.1 Susquehanna raised its Intel price target on this outlook.1

The shortage stems from memory supply chains failing to keep pace with an inflection in CPU demand driven by agentic AI workloads, according to Susquehanna analyst Christopher Rolland.1 These AI agents require significantly more memory and processing power than traditional applications, straining already tight component markets.

Memory shortages are hurting PC builds, which could negatively impact Intel's client computing business, Rolland noted.1 The constraints affect the entire computing stack, from consumer PCs to data center infrastructure needed for AI model deployment.

JPMorgan downgraded Qualcomm, citing near-term pressure in smartphone markets due to memory supply shortage and market share loss.1 The firm also downgraded optical component makers Fabrinet and Corning on supply chain concerns.1

The bottleneck advantages companies with secured memory supply chains and long-term contracts with memory manufacturers. Firms that locked in HBM and DRAM allocations months ago can continue deploying AI infrastructure while competitors face delays.

AI hardware stocks face volatility as investors weigh strong underlying demand against near-term revenue constraints. Companies unable to ship products due to memory shortages may miss Q1 targets despite healthy order books.

The Q1 peak suggests relief ahead. If Intel's projection holds, Q2 2026 could see sequential acceleration as memory supplies normalize and backlogged orders ship. Companies positioned to ramp quickly when constraints ease may capture outsized Q2 gains.

The shortage highlights vulnerabilities in AI infrastructure supply chains, where memory has emerged as a critical chokepoint alongside GPU availability and power capacity.

In this story

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com